<DOC>
	<DOCNO>NCT02764762</DOCNO>
	<brief_summary>The purpose study determine effect triple combination therapy anti-integrin [ vedolizumab intravenous ( IV ) ] , tumor necrosis factor ( TNF ) antagonist [ adalimumab subcutaneously ( SC ) ] , immunomodulator ( oral methotrexate ) endoscopic remission participant newly-diagnosed Crohn 's disease stratify high risk complication .</brief_summary>
	<brief_title>Triple Combination Therapy High Risk Crohn 's Disease</brief_title>
	<detailed_description>The drug test study call vedolizumab . Vedolizumab test treat people Crohn 's Disease . This study look endoscopic remission mucosal heal gastrointestinal tract people take vedolizumab triple combination therapy adalimumab methotrexate . The study enroll approximately 60 patient . Participants receive triple combination therapy include : - Vedolizumab 300 mg - Adalimumab 160/80/40 mg - Methotrexate 15 mg All participant receive vedolizumab IV infusion Weeks 0 , 2 , 6 , 14 22 along adalimumab 160 mg , SC injection Week 0 , 80 mg Week 2 , 40 mg Week 4 every 2 week thereafter Week 26 along methotrexate tablet orally , weekly Weeks 0 Week 34 . In monotherapy phase , participant receive vedolizumab IV infusion Weeks 30 , 38 , 46 , 54 , 62 , 70 , 78 , 86 , 94 102 . This multi-center trial conduct United States Canada . The overall time participate study 128 week . Participants make multiple visit clinic , plus final visit 18 week last dose study drug safety follow-up assessment . Participants also participate long-term safety questionnaire , phone , 18 week 26 week ( 6 month ) last dose study drug .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign dated write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is male nonpregnant , nonbreastfeeding female age 18 80 year , inclusive time Screening . 4 . Has initial diagnosis Crohn 's disease ( CD ) establish within 24 month prior enrollment involvement ileum and/or colon assess ileocolonoscopy . 5 . Has moderate severely active CD Screening define : 1 . Crohn 's disease activity index ( CDAI ) score ≥ 220 within 10 day prior enrollment , AND 2 . Centrally assessed simple endoscopic score Crohn 's disease ( SESCD ) score ≥7 ( ≥4 isolate ileal disease ) Screening , AND 3 . Elevated biomarker inflammation [ Creactive protein ( CRP ) &gt; 5 mg/L OR fecal calprotectin level &gt; 250 μg/g stool ) Screening . 6 . By investigator judgement , participant assess CD moderatehigh risk complication . Investigator judgement may include clinical assessment , Crohn 's Disease Personalized Risk Outcome Prediction Tool ( PROSPECT ) , criterion define 2014 American Gastroenterology Association ( AGA ) CD Clinical Care Pathway . 7 . May receive stable therapeutic dose conventional therapy CD . 8 . If corticosteroid , must stable dose oral corticosteroid 20 mg prednisone daily 9 mg budesonide daily least 7 day prior enrollment . 9 . If corticosteroid , must willing follow mandatory taper prednisone budesonide within 60 day enrollment . 10 . Must willing stop treatment 5aminosalicylate ( 5ASA ) , antibiotic , probiotic luminal CD enrollment . 11 . Male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 18 week last dose . 12 . Female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 18 week last dose . 13 . Family history colorectal cancer , personal history increase colorectal cancer risk , age &gt; 50 year , know risk factor must uptodate colorectal cancer surveillance ( may perform Screening standard care ) . Gastrointestinal ( GI ) Exclusion Criteria 1 . Has diagnosis ulcerative colitis ( UC ) indeterminate colitis . 2 . Has clinical evidence current abdominal abscess history prior abdominal abscess . 3 . Has know perianal fistula abscess . ( The participant may perianal fistula without abscess . ) 4 . Has know fistula ( perianal fistula ) . 5 . Had nonCD relate abdominal surgery within 6 month prior enrollment . 6 . Has prior CDrelated surgery OR CD complication require surgery time ( seton placement perianal fistula without abscess ) . 7 . Has history 2 non CD relate small bowel resection diagnosis short bowel syndrome . 8 . Has extensive non CD relate colonic resection , ie , subtotal total colectomy &lt; 15 cm colon remain . 9 . Has ileostomy , colostomy . 10 . Has history evidence adenomatous colonic polyp remove . 11 . Has history evidence colonic mucosal dysplasia . 12 . Has intolerance contraindication undergo ileocolonoscopy . 13 . Has know fix stricture stenosis intestine . Infectious Disease Exclusion Criteria 14 . Has identify congenital acquire immunodeficiency [ eg , common variable immunodeficiency , human immunodeficiency virus ( HIV ) infection ] . 15 . Has undergone organ transplantation . 16 . Has evidence active infection Screening . 17 . Infections require treatment oral ( PO ) intravenous ( IV ) antibiotic , antiviral , antifungal within 28 day enrollment . 18 . Has active latent tuberculosis ( TB ) , regardless treatment history , evidence following : 1 . History TB . 2 . A diagnostic TB test perform Screening positive , define : • A positive QuantiFERON test 2 successive indeterminate QuantiFERON test OR 3 . A tuberculin skin test reaction ≥10 mm ( ≥5 mm participant receive equivalent &gt; 15 mg/day prednisone ) 19 . Has history listeria , histoplasmosis , coccidioidomycosis , blastomycosis , candidiasis , aspergillosis , legionella , pneumocystosis . 20 . Has history bacterial , viral , infection due opportunistic pathogen . 21 . Has chronic hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . 22 . Has evidence active Clostridium difficile infection treatment C. difficile infection intestinal pathogen Screening . 23 . Has receive live vaccination within 28 day prior enrollment . General Exclusion Criteria 24 . Has inflammatory rheumatic disease ( eg , psoriasis , rheumatoid arthritis , ankylose spondylitis ) . 25 . Had surgical procedure require general anesthesia within 60 day prior enrollment plan undergo major surgery study period . 26 . Is take , take , required take exclude medication . 27 . Has receive either approve investigational biologic nonbiologic agent treatment inflammatory bowel disease ( IBD ) investigational protocol . 28 . Has prior exposure tumor necrosis factor ( TNF ) antagonist include infliximab , certolizumab pegol , golimumab , adalimumab , biosimilar TNF antagonist agent . 29 . Has prior exposure vedolizumab , natalizumab , efalizumab , rituximab . 30 . Has receive either approve investigational biologic agent treatment noninflammatory bowel disease ( IBD ) condition , localize injection ( eg , intraocular injection wet macular degeneration ) . 31 . Has history hypersensitivity allergy methotrexate , vedolizumab , adalimumab , component . 32 . Has medical history contraindicates use vedolizumab , adalimumab , methotrexate per drug 's package insert . 33 . Has condition , opinion investigator , may interfere participant 's ability comply study procedure . 34 . Has history lymphoma lymphoproliferative disease . 35 . Has history congestive heart failure ( New York Heart Association class III/IV ) unstable angina . 36 . Has renal insufficiency , ascites , pleural effusion , underlie liver disease . 37 . Has unstable uncontrolled cardiovascular , pulmonary , hepatic , renal , GI , genitourinary , hematological , coagulation , immunological , endocrine/metabolic , neurologic , medical disorder , opinion investigator , would confound study result compromise participant safety . 38 . Has gastric bypass surgery . 39 . Has symptom shortness breath cough and/or diagnosis clinically significant lung disease . 40 . Has history malignancy , except follow : adequatelytreated nonmetastatic basal cell skin cancer ; squamous cell skin cancer adequately treat recur least 1 year prior Screening ; history cervical carcinoma situ adequately treat recur least 3 year prior Screening . Participants remote history malignancy ( eg , &gt; 10 year since completion curative therapy without recurrence ) consider base nature malignancy therapy receive ; must discuss sponsor casebycase basis prior enrollment . 41 . Has history major neurological disorder , include stroke , central nervous system demyelinate disease , brain tumor , neurodegenerative disease . 42 . Has positive progressive multifocal leukoencephalopathy ( PML ) subjective symptom checklist prior administration study drug . 43 . Has history preexist blood dyscrasia , bone marrow hypoplasia , leukopenia ( WBC count &lt; 3 × 10^9/L ) , thrombocytopenia ( platelet count &lt; 100 × 10/L ) , significant anemia ( hemoglobin level &lt; 8 g/dL ) . 44 . Has rare hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 45 . Has follow laboratory abnormality Screening period : 1 . Hemoglobin level &lt; 8 g/dL . 2 . WBC count &lt; 3 x 10^9/L . 3 . Lymphocyte count &lt; 0.5 x 10^9/L . 4 . Platelet count &lt; 100 x 10^9/L &gt; 1200 x 10^9/L . 5 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 upper limit normal ( ULN ) . 6 . Alkaline phosphatase &gt; 1.5 x ULN . 7 . Renal dysfunction ( serum creatinine concentration great 1.5 mg per deciliter [ 133 µmol per liter ] ) estimate glomerular filtration rate ( eGFR ) &lt; 50 mL/min/1.73 m^2 Screening Note : Retesting laboratory value screen interval may consider consultation Medical Monitor . 46 . Has history high alcohol consumption ( 7 drink per week ) , history prior alcohol abuse within 5 year prior enrollment , alcoholic liver disease , withdrawal symptom , history illicit drug use . 47 . Has active psychiatric problem , investigator 's opinion , may interfere compliance study procedure . 48 . Is unable attend study visit comply study procedure . 49 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g , spouse , parent , child , sibling ) may consent duress . 50 . Body mass index &gt; 35 . 51 . If female , participant pregnant lactate intend become pregnant , , within 6 month participate study ; intend donate ova time period . 52 . If male , participant intend father child donate sperm course study 6 month thereafter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>